Among patients with relapsed myeloma, median progression-free survival was approximately 3 years with a regimen including belantamab mafodotin, as compared with 13 months with a regimen including an anti-CD38 antibody.
The New England Journal of Medicine: Search Results in Hematology/Oncology
